SHARESIFT
Healthcare · data ~15-min delayed
1,142.85 USD -0.61%
| Price | 1,142.85 USD |
| Day change | -0.61% |
| Market cap | 1.02T |
| 52-week range | 783.85 – 1,292.65 |
| P/E (trailing) | 38.3 |
| Dividend yield | 0.61% |
| Payout ratio | 21.69% |
| Return on equity | 102.29% |
| Debt / equity | 162% |
| Beta | 0.50 |
| Sector | Healthcare |
| Value score | 24 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Eli Lilly and Company (LLY) scores 24/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 38.3 times trailing earnings and is classified in Healthcare. The dividend yield is 0.61%, paid from 22% of earnings. Return on equity is 102%, with debt at 162% of equity. On its filings it passes 4 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 4 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 10.50 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.